ReviewBreast (Edinburgh, Scotland)2025
Improving survival outcomes of people with ABC: a global expert review and call-to-action for 2025-2035 (Goal 1).
Review in Breast (Edinburgh, Scotland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Phase III Study.Cancer communications (London, England) · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advanced breast cancer (ABC) remains a significant public health challenge, accounting for the majority of the ∼670,000 breast cancer deaths globally in 2022. In the past decade, significant improvements in survival were seen across all ABC subtypes and patient populations, but disparities remain and ABC continues to be an incurable disease for most people. This manuscript provides an overview of the survival improvements reported for each ABC subtype in clinical trials and in real-world studies since 2015. It highlights where disparities remain and outlines recommendations for the ABC community over the next decade to further improve survival. It summarizes findings from reviews conducted for the ABC Global Alliance's Global Decade Report 2.0. The main findings are: a) Clinical trials showed significant survival gains for ABC in 2015-2025, particularly for hormone receptor-positive and human epidermal growth factor 2 receptor (HER2)-positive subtypes; b) Real-world data mirrors survival trends seen in ABC clinical trials; c) Biomarker-driven treatments offer benefits in ABC, but testing is inconsistent from healthcare professionals; d) Survival disparities remain between ABC subtypes; e) Survival in ABC remains poor compared to early breast cancer. The findings from the ABC Global Alliance's Global Decade Report 2.0 have informed the development of a new ABC Global Charter. The ABC Global Charter 2.0 defines ten new achievable and measurable goals for the decade 2025-2035, aiming at improving the lives of people living with ABC worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.